Tower Research Capital LLC TRC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Tower Research Capital LLC TRC grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 338.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,242 shares of the company's stock after purchasing an additional 14,852 shares during the quarter. Tower Research Capital LLC TRC's holdings in IDEAYA Biosciences were worth $495,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. R Squared Ltd purchased a new position in IDEAYA Biosciences in the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. lifted its stake in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after buying an additional 853 shares during the period. KBC Group NV lifted its stake in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after buying an additional 1,923 shares during the period. Cibc World Markets Corp acquired a new stake in IDEAYA Biosciences during the fourth quarter worth approximately $203,000. Finally, Mariner LLC grew its stake in IDEAYA Biosciences by 9.8% in the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after acquiring an additional 869 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IDYA has been the topic of several analyst reports. Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Stock Down 1.2 %

Shares of IDEAYA Biosciences stock traded down $0.25 during trading hours on Monday, hitting $20.68. The company's stock had a trading volume of 246,078 shares, compared to its average volume of 967,329. The business has a fifty day moving average of $17.90 and a 200 day moving average of $23.00. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The company has a market capitalization of $1.81 billion, a PE ratio of -6.27 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. On average, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.